Study Group: Rituxan Prescribers for NHL: Lymphoma Oncologists (US)(?)
Council Members in this Study Group: 25
Request a survey with this Study Group
Leading Experts in this Study Group
Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Staff Physician
Ironwood Cancer & Research Center
Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
The author argues that transparency in healthcare will be an important step forward for the consumer.
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes. Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.
Avastin ( Roche/Genentech) extended time to progression when combined with Docotaxel ( Sanofi-Aventis) in patients with metastatic breast cancer as compared to Docotaxel alone, but did not prolong survival. Unlike approval by the FDA,the EMEA is more cost conscious and may be reluctant to...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Assistant Professor
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms